Anti-stathmin gene therapy (Gradalis)

N/A

Report date: 2024/09/10 15:48:24

Base Information

Drug NameAnti-stathmin gene therapy (Gradalis)
Drug Alias Namepbi-shSTMN1 LPpbi-shRNA STMN1 LP
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > short hairpin RNA
Mechanisms of ActionStathmin inhibitors
TargetsStathmin
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGradalis Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGradalis Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursNeoplasm MetastasisNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A